The abstract is read at the publisher; the summary is JClub's.
In 137 children with high-risk neuroblastoma receiving GD2/GD3 vaccination plus oral β-glucan, microbiome-perturbing antibiotics are linked to inferior progression-free survival, and impair vaccine antibody responses in mice.
- Why it matters: Therapeutic cancer vaccination may depend on gut microbes, but how the intestinal microbiome shapes GD2/GD3 vaccine immunogenicity and outcomes in children is unclear.
- What they did: The study profiled gut microbiomes and measured vaccine immunogenicity and clinical outcomes in 137 pediatric patients, and tested antibiotic effects on vaccine-induced anti-GD2 IgG and tumor growth in a complementary mouse model.
- The result: Among patients vaccinated in first remission, higher α-diversity and Lachnospiraceae enrichment (including Blautia) are associated with higher anti-GD2 IgG1 responses, while higher Clostridia abundance and greater microbiome maturation discrepancy are linked to PFS differences. In mice, antibiotics reduce anti-GD2 IgG responses and accelerate tumor growth.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.